Eiger Biopharmaceuticals Inc (EIGRQ)

Currency in USD
8.500
0.000(0.00%)
Delayed Data·
Showing Eiger Biopharma historical data. For real-time data please try another search
Day's Range
8.0008.500
52 wk Range
1.10016.000
Key Statistics
Prev. Close
8.5
Open
8
Day's Range
8-8.5
52 wk Range
1.1-16
Volume
-
Average Volume (3m)
9.9K
1-Year Change
-32.54%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Eiger Biopharmaceuticals Inc Company Profile

On September 30, 2024, Eiger BioPharmaceuticals, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia. The company is headquartered in Palo Alto, California.

Earnings

Latest Release
Aug 01, 2024
EPS / Forecast
-- / -0.26
Revenue / Forecast
-609,790.00 / 5.02M
EPS Revisions
Last 90 days

EIGRQ Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.